Australia Welcomes Advent Of INN Prescribing
Reforms Negotiated By GBMA As Part Of Strategic Agreement With Government
Prescribing reforms introduced from the start of February in Australia will see doctors prioritize active ingredients over brand names, following negotiations with government by the country’s GBMA off-patent industry association.
You may also be interested in...
Legislation setting out measures to mitigate shortages in Australia has been passed by the country’s senate, incorporating into law key provisions of new five-year pact between the off-patent industry and the government.
AbbVie is spreading confusion among Australian doctors and patients with anti-competitive materials designed to fend off biosimilar adalimumab competition to Humira, according to a local biosimilars industry association.
Lupin has broadened its reach in Australia after agreeing a deal to buy local generics developer and distributor Southern Cross.